Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
March 11 2020 - 7:00AM
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company
dedicated to improving life through the application of its
pioneering, proprietary ARCUS® genome editing platform,
announced today that Geno Germano, President and CEO of Elucida
Oncology, has been appointed to the company’s Board of Directors.
“Over the course of his career, Geno has been a
leader at some of the world’s most innovative companies, including
Intrexon, Pfizer, Wyeth and Johnson & Johnson. This experience,
together with his expertise in oncology as CEO of Elucida, will be
invaluable to Precision as we work to deliver on the promise of
genome editing to improve human health and wellness,” commented
Matt Kane, CEO and co-founder of Precision BioSciences. “We welcome
him and look forward to working together.”
“I am excited to join Precision BioSciences at this
important time, as they continue to advance multiple innovative
programs in allogeneic cell therapy and in vivo gene correction
into clinical trials,” said Mr. Germano. “My personal goal is to
work with innovative companies who are driving real therapeutic
benefit for patients in need. Precision’s differentiated approach
to genome editing through ARCUS, along with its expanding clinical
portfolio, has tremendous potential to deliver transformative
advancements in medicine across multiple different diseases.”
Mr. Germano is a 30-year veteran of the
pharmaceutical and life sciences industry who, prior to joining
Elucida Oncology, served as President of Intrexon, a leader in the
application of synthetic biology. He has also held multiple senior
roles at major pharmaceutical corporations including Pfizer, Wyeth
and Johnson & Johnson. At Pfizer, he led the Global Innovative
Pharmaceutical business, cultivating a $14 billion operation and
guiding the development of an extensive portfolio of products in
the cardiovascular, immunology, metabolic disease, neuroscience and
rare disease areas. He also served as Pfizer’s President and
General Manager of the Specialty Care, Vaccines and Oncology
business units. At Wyeth Pharmaceuticals, Mr. Germano served as
President of Wyeth U.S., President of the Global Pharmaceutical and
Women's Healthcare business and as Executive Vice President of the
Vaccines. He has been a member of the Group of Fifty (G50) and
served on the Board of the Biotechnology Innovation Organization
(BIO), where he was a member of the Executive Committee. Mr.
Germano has also served on the Advisory Board of the Healthcare
Businesswomen's Association, and he currently serves on the board
of directors at Sage Therapeutics (NASDAQ:SAGE). He received his
Bachelor of Science degree at the Albany College of Pharmacy and
Health Sciences.
About Precision BioSciences,
Inc.Precision BioSciences is dedicated to improving life
(DTIL) through its proprietary genome editing platform, ARCUS.
Precision leverages ARCUS in the development of its product
candidates, which are designed to treat human diseases and create
healthy and sustainable food and agriculture solutions. Precision
is actively developing product candidates in three innovative
areas: allogeneic CAR T immunotherapy, in vivo gene correction, and
food. For more information regarding Precision, please
visit www.precisionbiosciences.com.
Investor Contact: Nick Riddle
Precision BioSciences Tel. (919)
314-5512IR@precisionbiosciences.com
Media Contact:Cory TrombleeScient
Public RelationsTel. (617) 571-7220cory@scientpr.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024